SMSPHARMA vs THEMISMED: Stock Comparison

SMS Pharmaceuticals Limited vs Themis Medicare Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

SMS Pharmaceuticals Limited is the larger company by market capitalisation. SMS Pharmaceuticals Limited shows a lower P/E, a higher ROE and lower leverage, while Themis Medicare Limited shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of SMS Pharmaceuticals Limited and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, SMSPHARMA is more favourable on 8 of 13 scored metrics and THEMISMED on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SMSPHARMA is the larger company
₹3,560 Cr vs ₹972 Cr
P/E Ratio
SMSPHARMA has a lower P/E
34.95x vs 883.33x
P/B Ratio
THEMISMED has a lower P/B
2.45x vs 4.54x
EPS
SMSPHARMA has higher earnings per share
₹11.17 vs ₹0.12
Dividend Yield
THEMISMED has a higher dividend yield
0.43% vs 0.1%
Revenue Growth (TTM YoY)
THEMISMED has faster revenue growth
6.7% vs -4.1%
EPS Growth (TTM YoY)
SMSPHARMA has faster EPS growth
49.2% vs 0%
Qtr Sales Growth
THEMISMED has stronger quarterly sales growth
6.74% vs -4.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSMSPHARMATHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSMSPHARMATHEMISMED
Live Price₹380.75₹105.78
Day Change-2.85%-1.99%
Volume1.03 L34,271
52-Week High₹447.8₹148
52-Week Low₹207.99₹64.95
Distance from 52W High-14.97%-28.53%

Valuation

MetricSMSPHARMATHEMISMED
Market Cap₹3,560 Cr₹972 Cr
P/E Ratio34.95x883.33x
P/B Ratio4.54x2.45x
EPS₹11.17₹0.12
Book Value₹81.83₹43.06
Dividend Yield0.1%0.43%

Growth

MetricSMSPHARMATHEMISMED
Revenue Growth (TTM YoY)-4.1%6.7%
EPS Growth (TTM YoY)49.2%0%
Qtr Sales Growth-4.13%6.74%
Qtr Profit Growth61%192%

Profitability & Leverage

MetricSMSPHARMATHEMISMED
ROE14.3%0.29%
ROCE13.3%2.74%
Net Margin11.5%0.33%
Operating Margin19.3%-2.9%
Debt to Equity0.46x25.11x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSMSPHARMATHEMISMED
Promoter Holding68.07%57.5%
FII Holding0.65% 0.34 pp0.01% 0.1 pp
DII Holding2.83% 0.19 pp0.01%
Public Holding28.45% 0.15 pp32.87% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SMS Pharmaceuticals Limited and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.